Onconano Medicine, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-12-29
- Employees
- 11
- Market Cap
- -
- Website
- http://www.onconano.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- Conditions
- Lymphoma, Non-HodgkinFollicular LymphomaBladder CancerMetastatic CancerTumor RecurrenceUveal Melanoma, RecurrentCarcinoma in SituSkin CancerTumor, SolidTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06022029
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸BRCR Global, Tamarac, Florida, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
- Conditions
- Lung Cancer
- Interventions
- Procedure: Tumor resection surgery
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05048082
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04950166
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸The Ohio State University Wexner Medical Center / James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaProstate CancerBreast CancerColorectal CancerOvarian CancerNon-small Cell Lung CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03735680
- Locations
- 🇺🇸
The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States